Browse the evidence

Higher consumption of animal-based foods may mitigate the risk of elevated TyG among women.

Encouraging a balanced intake of animal-based foods may be beneficial for women at risk of elevated TyG.

Powerlifters trained an average of 4.25 times per week, performing competition-style lifts at specific frequencies: squat 1.64 times, bench press 2.48 times, and deadlift 1.37 times per week.

Trainers should consider the average training frequency and specific lift focus when designing programs for powerlifters.

Programming decisions for competition lifts were influenced by athlete characteristics such as gender, age, and training status.

Coaches should consider individual athlete characteristics when designing training programs for powerlifters.

Plant-based diets improve cardiovascular health by modulating gut microbiota and metabolites.

Practitioners may consider recommending plant-based diets for cardiovascular health.

Latina women experiencing food insecurity consumed fewer vegetables compared to those with food security (1.7 vs. 3.0 servings, p=0.02).

Practitioners should address food security to improve vegetable intake among Latina women.

Women with nutrition insecurity consumed fewer servings of vegetables compared to participants with nutrition security (1.7 vs. 2.5 servings, p=0.01).

Practitioners should focus on improving nutrition security to enhance vegetable intake.

Participants with food and nutrition insecurity had more symptoms of depression and anxiety compared to participants with food and nutrition security (p<0.05).

Practitioners should consider mental health support for those facing food and nutrition insecurity.

Adherence to vegan and WFPB diets for ≥2 years is associated with lower BMI compared to <2 years.

Long-term adherence to vegan and WFPB diets may enhance weight loss outcomes.

MR-O and Conv-O similarly increased fecal fat percentage from 3.8% to 13.5%, confirming pharmacodynamic equivalence.

Both formulations can be considered equally effective in increasing fecal fat excretion.

The new weight loss product MR-OA retains the dietary energy loss pathway used in Conv-O.

MR-OA can be expected to function similarly to Conv-O in promoting fat loss.

Co-stimulation of GLP-1 with other receptors provides additional therapeutic benefits.

Combining GLP-1 therapy with other hormonal treatments may enhance effectiveness.

Obesity-related hypertension is a significant contributor to cardiovascular morbidity and mortality.

Healthcare providers should prioritize addressing obesity to mitigate hypertension and related cardiovascular risks.

Behavioral support is necessary to maximize the benefits of incretin therapy.

Practitioners should integrate behavioral support strategies into incretin therapy plans.

Recent studies highlight the efficacy of diabetic agents and other novel therapies in shaping obesity-associated hypertension management guidelines.

Healthcare providers should consider incorporating diabetic agents and novel therapies into treatment plans.

Both 0839 and 0833 improved metabolic parameters and reduced body weight primarily by fat mass reduction.

These compounds may be effective for fat loss and improving metabolic health.

Tirzepatide demonstrated a positive impact on the cardiovascular system.

Tirzepatide may be beneficial for patients with cardiovascular concerns related to diabetes.

GLP-1 receptor agonists (GLP-1RA) significantly reduce major adverse cardiovascular events (MACE) with a pooled hazard ratio of 0.86.

GLP-1RA can be recommended for reducing cardiovascular risks in patients with type 2 diabetes and obesity.

Both systolic blood pressure (SBP) and weight reductions are independently associated with reduced MACE risk.

Weight management and blood pressure control should be emphasized in treatment plans for these patients.

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in obesity management is increasing.

Practitioners should be aware of the growing role of GLP-1 RAs in obesity treatment.

Endobariatrics (EBT) offers durable weight loss with low complication rates.

EBT can be considered a viable option for patients seeking weight loss with minimal risks.

The combination of an amylin analog and other anti-obesity peptide drugs has demonstrated higher clinical efficacy in reducing body weight than monotherapy.

Combination therapies may be more effective for weight loss than single-drug treatments.

Obesity is associated with many health risks, including hypertension, hyperlipidemia, T2D, CHD, stroke, gallbladder disease, osteoarthritis, sleep apnea, respiratory problems, and some cancers.

Healthcare practitioners should be aware of the extensive health risks associated with obesity.

Up to 40% of weight loss following treatment with GLP-1RA is accounted for by lean mass.

Clinicians should be aware of potential lean mass loss when prescribing GLP-1RA therapies.

Early change in eating-related self-regulation is a stronger predictor of longer-term change in eating-related self-efficacy than the reverse.

Focusing on enhancing self-regulation may be crucial for improving self-efficacy in obesity treatment.